INSIGHT: Nebius Honors the AI That Could Save Lives in Healthcare

Omniscope and Phylo: Two Ambitious Scientific Ventures

The Genomics category was won by Omniscope, ahead of Twig Bio and DELFI Diagnostics, while the Biopharma category crowned Phylo in first place, followed by Virgo and Decoy Therapeutics. These companies harness the massive computing power provided by Nebius to accelerate research processes that historically took years of work in traditional laboratories.

The Genomics category, in particular, illustrates the sheer scale of the transformative potential of applied AI: mapping complex genetic variations across entire populations is now possible at a speed that would have seemed unrealistic just a decade ago.

Continuing the Legacy of the Inaugural 2025 Edition

At the first edition held in June 2025, Nebius had already recognized companies such as Ataraxis AI, whose cancer treatment prediction platform achieved 30% greater accuracy than standard genomic tests, clinically validated across more than 7,500 patients at 15 institutions. This continuity between the two editions demonstrates that the competition is not merely a one-off media stunt, but is part of a long-term strategy to support biomedical innovation.

The number of applications has also increased, rising from 257 in the first edition to a broader pool of international participants for 2026—a tangible sign of the competition’s growing credibility within the global health startup ecosystem.

I find this continuity reassuring: too many technology competitions fizzle out after a highly publicized first edition, whereas this one, on the contrary, seems to be gaining in scope and scientific rigor year after year.

GPU credits that are sometimes worth more than traditional financing

For many startups in the life sciences sector, access to sufficient computing power is often a greater obstacle than traditional venture capital funding. The computing credits offered by Nebius—which can reach up to $100,000 for top finishers—enable these companies to train large-scale artificial intelligence models without having to devote a disproportionate share of their limited capital to technical infrastructure.

This approach, which combines public recognition with concrete material support, sets the Nebius competition apart from mere honorary ceremonies: it offers a real and immediately actionable competitive advantage to the winning companies as they compete against better-funded rivals.

A European infrastructure gaining ground against American giants

Dr. Ilya Burkov, Global Head of Growth for Life Sciences and Healthcare at Nebius, with over 15 years of experience spanning clinical medicine, biotechnology, and cloud computing, embodies the company’s commitment to positioning itself as a credible European alternative to American cloud computing giants. Nebius has also recently expanded its presence in the United Kingdom with one of the country’s first advanced deployments of NVIDIA infrastructure.

This European geographic expansion is part of a broader context in which the West is seeking to reduce its excessive dependence on a limited number of AI infrastructure providers—a diversification deemed strategically sound in the face of the growing concentration of the global advanced computing market.

I believe that the diversification of European AI infrastructure—as exemplified here by Nebius—is a strategically sound development for the West: relying on too few providers, even allied ones, carries risks that recent global trade tensions have clearly demonstrated.

The global race to apply AI to healthcare is accelerating

Behind the philanthropic facade of this competition lies a broader geopolitical issue: the global race to dominate the application of artificial intelligence to human health. China is investing heavily in this sector, seeking to combine its vast national medical databases with its growing capabilities in advanced computing—a strategy that concerns many Western analysts regarding data security and biomedical intellectual property.

In the face of this competition, initiatives like Nebius’s strengthen the Western ecosystem’s ability to quickly identify and support the most promising innovations before they are captured or replicated by rival state actors less concerned with Western ethical standards regarding the protection of personal medical data.

Academic Partnerships That Strengthen the Western Ecosystem

Several winners and honorable mentions from previous editions of the Nebius competition have established partnerships with prestigious academic institutions, including Microsoft Research and leading university hospitals. These collaborations reinforce an integrated Western ecosystem where academic research, venture capital, and advanced cloud infrastructure work in concert rather than in separate silos.

This structural integration constitutes, in my view, one of the West’s true and sustainable competitive advantages over the more centralized and less collaborative models adopted by certain international technology rivals.

I believe that this seamless integration between Western academic research, venture capital, and private cloud infrastructure represents a structural advantage that our technology rivals are still struggling to replicate despite their massive investments.

Validate Clinically Before Celebrating Commercially

Despite the legitimate enthusiasm generated by this list of winners, it is important to remember that the majority of the award-winning technologies remain in early stages of development and still require rigorous clinical validation before any large-scale deployment in Western public health care systems. The recent history of AI applied to medicine is rife with examples of technologies that showed promise in the lab but failed to live up to expectations in large-scale clinical trials.

This methodological caution in no way detracts from the merit of the award-winning companies, but it serves as a useful reminder that the path from a prototype honored at a ceremony in London to a medical tool actually deployed among millions of patients remains long, costly, and fraught with legitimate regulatory hurdles.

The Sensitive Issue of Medical Data Protection

The rapid rise of these technologies also raises legitimate questions regarding the protection of personal medical data used to train these artificial intelligence models. European regulators, already vigilant on these issues through strict regulatory frameworks, will need to continue adapting their oversight mechanisms as these technologies become more sophisticated and gain widespread clinical adoption.

A careful balance between encouraging innovation and rigorously protecting personal data remains essential to preserving Western public trust in these emerging medical technologies—a trust that itself constitutes a competitive advantage that our rivals, who are less scrupulous about privacy, do not necessarily possess.

I believe that this European regulatory vigilance regarding the protection of medical data—sometimes criticized as a barrier to innovation—actually constitutes a long-term trust advantage that the West would be wrong to sacrifice in order to artificially accelerate its pace of technological adoption.

A panel of experts from the biotechnology, pharmaceutical, and venture capital sectors

The competition’s scientific credibility rests largely on its panel of independent judges, which for the inaugural edition consisted of 19 experts from leading biotechnology, pharmaceutical, and specialized venture capital firms. This diversity of expertise allows entries to be evaluated based on scientific, clinical, and commercial criteria, reducing the risk of rewarding projects that look promising on paper but lack real-world viability.

This rigorous evaluation process sets the Nebius competition apart from mere technology-focused public relations stunts: it demonstrates a serious commitment to identifying innovations with genuine potential for clinical impact, rather than simply impressive but fruitless technological demonstrations.

Honorable Mentions That Broaden the Talent Pool

Beyond the main winners, the competition also awards honorable mentions to dozens of additional companies, making it possible to identify a much broader pool of emerging talent than the official podium alone could reflect. This broader approach benefits the entire ecosystem, even companies not selected for the top three spots in each category.

This relative generosity in identifying talent strengthens the competition’s reputation among venture capitalists, who now regularly consult the full list of honorable mentions to identify future investment opportunities in the digital health sector.

I find this system of expanded honorable mentions clever: it transforms a competition into a true tool for mapping global innovation in healthcare, far beyond the three official winners in each category.

From a simple GPU provider to a strategic industry partner

Over the past two years, Nebius has profoundly transformed its business positioning, evolving from a mere provider of raw computing power to a strategic partner specializing by sector, with healthcare and the life sciences now constituting a priority area explicitly endorsed by the company’s management. This specialization allows Nebius to differentiate itself from competitors offering more general-purpose infrastructure that is less suited to the specific needs of biomedical research.

Client companies such as Prima Mente, which develops foundational models to understand the human brain, and Helical, which helps pharmaceutical companies accelerate their virtual experiments, are concrete examples of Nebius’s sector-specific specialization strategy.

An NVIDIA Partnership That Strengthens Its European Position

In March 2026, Nebius announced an expanded partnership with NVIDIA aimed at strengthening its cloud infrastructure dedicated to large-scale artificial intelligence—a collaboration that further solidifies the company’s technical credibility with demanding institutional clients in the healthcare sector. This technical alliance enables Nebius to offer computing capabilities comparable to those of the largest U.S. providers, while maintaining European governance and data centers.

This combination of cutting-edge U.S. technology and European governance could prove particularly reassuring for European healthcare companies seeking to comply with strict regulatory requirements for data protection while benefiting from world-class computing power.

I believe that this combination of cutting-edge American technology and rigorous European governance represents precisely the kind of transatlantic balance the West needs to remain competitive without sacrificing its ethical standards.

What This List Really Reveals About the State of Western Innovation

Beyond the names of companies still largely unknown to the general public, this AI Discovery Awards list reveals a vibrant Western innovation ecosystem that is geographically diverse and methodologically rigorous. The combination of generous computing infrastructure, validation by a panel of independent judges from the biotechnology and finance sectors, and a broad international reach outlines a replicable model that other Western technology players would do well to emulate.

This dynamic, however modest it may seem compared to the spectacular announcements from American tech giants, illustrates the continued vitality of the Western innovation ecosystem as it applies to human health.

A development to watch to gauge the winners’ actual progress

The true test of this competition will unfold in the coming years, when observers will be able to assess how many of these award-winning companies have effectively transformed their promising prototypes into medical solutions that are actually being deployed with real patients. The 2025 edition had already identified companies such as Ataraxis AI, whose clinical progress warrants close monitoring in the coming months.

For now, the 2026 list of winners confirms that the West retains a genuine methodological and institutional lead in the application of artificial intelligence to healthcare—an advantage it will nevertheless need to continue actively cultivating in the face of increasingly determined international competition.

I conclude this analysis convinced that the true technological battle of the coming decade will be fought as much in biomedical laboratories as in data centers, and that the West has every reason to relentlessly pursue this type of initiative.

By Maxime Marquette, columnist